Bispecific antibody neutralizes circulating SARS-CoV-2 variants, prevents escape and protects mice from disease
Summary Neutralizing antibodies targeting the receptor binding domain (RBD) of the SARS-CoV-2 Spike (S) are among the most promising approaches against coronavirus disease 2019 (COVID-19)1,2. We developed a bispecific, IgG1-like molecule (CoV-X2) based on two antibodies derived from COVID-19 convalescent donors, C121 and C1353. CoV-X2 simultaneously binds two independent sites on the RBD and, unlike its parental antibodies, prevents detectable S binding to Angiotensin-Converting Enzyme 2 (ACE2), the virus cellular receptor. Furthermore, CoV-X2 neutralizes SARS-CoV-2 and its variants of concern, as well as the escape mutants generated by the parental monoclonals. In a novel animal model of SARS-CoV-2 infection with lung inflammation, CoV-X2 protects mice from disease and suppresses viral escape. Thus, simultaneous targeting of non-overlapping RBD epitopes by IgG-like bispecific antibodies is feasible and effective, combining into a single molecule the advantages of antibody cocktails..
Medienart: |
Preprint |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
bioRxiv.org - (2021) vom: 08. März Zur Gesamtaufnahme - year:2021 |
---|
Sprache: |
Englisch |
---|
Links: |
Volltext [kostenfrei] |
---|
doi: |
10.1101/2021.01.22.427567 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
XBI019792697 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | XBI019792697 | ||
003 | DE-627 | ||
005 | 20230429095256.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210125s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1101/2021.01.22.427567 |2 doi | |
035 | |a (DE-627)XBI019792697 | ||
035 | |a (DE-599)biorXiv10.1101/2021.01.22.427567 | ||
035 | |a (biorXiv)10.1101/2021.01.22.427567 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | |a 570 |q DE-84 | |
100 | 1 | |a De Gasparo, Raoul |e verfasserin |4 aut | |
245 | 1 | 0 | |a Bispecific antibody neutralizes circulating SARS-CoV-2 variants, prevents escape and protects mice from disease |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Summary Neutralizing antibodies targeting the receptor binding domain (RBD) of the SARS-CoV-2 Spike (S) are among the most promising approaches against coronavirus disease 2019 (COVID-19)1,2. We developed a bispecific, IgG1-like molecule (CoV-X2) based on two antibodies derived from COVID-19 convalescent donors, C121 and C1353. CoV-X2 simultaneously binds two independent sites on the RBD and, unlike its parental antibodies, prevents detectable S binding to Angiotensin-Converting Enzyme 2 (ACE2), the virus cellular receptor. Furthermore, CoV-X2 neutralizes SARS-CoV-2 and its variants of concern, as well as the escape mutants generated by the parental monoclonals. In a novel animal model of SARS-CoV-2 infection with lung inflammation, CoV-X2 protects mice from disease and suppresses viral escape. Thus, simultaneous targeting of non-overlapping RBD epitopes by IgG-like bispecific antibodies is feasible and effective, combining into a single molecule the advantages of antibody cocktails. | ||
700 | 1 | |a Pedotti, Mattia |e verfasserin |4 aut | |
700 | 1 | |a Simonelli, Luca |e verfasserin |4 aut | |
700 | 1 | |a Nickl, Petr |e verfasserin |4 aut | |
700 | 1 | |a Muecksch, Frauke |e verfasserin |4 aut | |
700 | 1 | |a Cassaniti, Irene |e verfasserin |4 aut | |
700 | 1 | |a Percivalle, Elena |e verfasserin |4 aut | |
700 | 1 | |a Lorenzi, Julio C. C. |e verfasserin |4 aut | |
700 | 1 | |a Mazzola, Federica |e verfasserin |4 aut | |
700 | 1 | |a Magrì, Davide |e verfasserin |4 aut | |
700 | 1 | |a Michalcikova, Tereza |e verfasserin |4 aut | |
700 | 1 | |a Haviernik, Jan |e verfasserin |4 aut | |
700 | 1 | |a Honig, Vaclav |e verfasserin |4 aut | |
700 | 1 | |a Mrazkova, Blanka |e verfasserin |4 aut | |
700 | 1 | |a Polakova, Natalie |e verfasserin |4 aut | |
700 | 1 | |a Fortova, Andrea |e verfasserin |4 aut | |
700 | 1 | |a Tureckova, Jolana |e verfasserin |4 aut | |
700 | 1 | |a Iatsiuk, Veronika |e verfasserin |4 aut | |
700 | 1 | |a Girolamo, Salvatore Di |e verfasserin |4 aut | |
700 | 1 | |a Palus, Martin |e verfasserin |4 aut | |
700 | 1 | |a Zudova, Dagmar |e verfasserin |4 aut | |
700 | 1 | |a Bednar, Petr |e verfasserin |4 aut | |
700 | 1 | |a Bukova, Ivana |e verfasserin |4 aut | |
700 | 1 | |a Bianchini, Filippo |e verfasserin |4 aut | |
700 | 1 | |a Mehn, Dora |e verfasserin |4 aut | |
700 | 1 | |a Nencka, Radim |e verfasserin |4 aut | |
700 | 1 | |a Strakova, Petra |e verfasserin |4 aut | |
700 | 1 | |a Pavlis, Oto |e verfasserin |4 aut | |
700 | 1 | |a Rozman, Jan |e verfasserin |4 aut | |
700 | 1 | |a Gioria, Sabrina |e verfasserin |4 aut | |
700 | 1 | |a Camilla Sammartino, Josè |e verfasserin |4 aut | |
700 | 1 | |a Giardina, Federica |e verfasserin |4 aut | |
700 | 1 | |a Gaiarsa, Stefano |e verfasserin |4 aut | |
700 | 1 | |a Hammarström, Qiang Pan |e verfasserin |4 aut | |
700 | 1 | |a Barnes, Christopher O. |e verfasserin |4 aut | |
700 | 1 | |a Bjorkman, Pamela J. |e verfasserin |4 aut | |
700 | 1 | |a Calzolai, Luigi |e verfasserin |4 aut | |
700 | 1 | |a Piralla, Antonio |e verfasserin |4 aut | |
700 | 1 | |a Baldanti, Fausto |e verfasserin |4 aut | |
700 | 1 | |a Nussenzweig, Michel C. |e verfasserin |4 aut | |
700 | 1 | |a Bieniasz, Paul D. |e verfasserin |4 aut | |
700 | 1 | |a Hatziioannou, Theodora |e verfasserin |4 aut | |
700 | 1 | |a Prochazka, Jan |e verfasserin |4 aut | |
700 | 1 | |a Sedlacek, Radislav |e verfasserin |4 aut | |
700 | 1 | |a Robbiani, Davide F. |e verfasserin |4 aut | |
700 | 1 | |a Ruzek, Daniel |e verfasserin |4 aut | |
700 | 1 | |a Varani, Luca |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 08. März |
773 | 1 | 8 | |g year:2021 |g day:08 |g month:03 |
856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.01.22.427567 |z kostenfrei |3 Volltext |
912 | |a GBV_XBI | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |j 2021 |b 08 |c 03 | ||
953 | |2 045F |a 570 |